Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Synthesis and evaluation of antiproliferative microtubule-destabilising combretastatin A-4 piperazine conjugates.

O'Boyle NM, Ana G, Kelly PM, Nathwani SM, Noorani S, Fayne D, Bright SA, Twamley B, Zisterer DM, Meegan MJ.

Org Biomol Chem. 2019 Jun 26;17(25):6184-6200. doi: 10.1039/c9ob00558g.

PMID:
31173031
2.

The XIAP inhibitor embelin sensitises malignant rhabdoid tumour cells to TRAIL treatment via enhanced activation of the extrinsic apoptotic pathway.

Coyle R, Slattery K, Ennis L, O'sullivan MJ, Zisterer DM.

Int J Oncol. 2019 Jul;55(1):191-202. doi: 10.3892/ijo.2019.4804. Epub 2019 May 20.

PMID:
31115498
3.

3-Vinylazetidin-2-Ones: Synthesis, Antiproliferative and Tubulin Destabilizing Activity in MCF-7 and MDA-MB-231 Breast Cancer Cells.

Wang S, Malebari AM, Greene TF, O'Boyle NM, Fayne D, Nathwani SM, Twamley B, McCabe T, Keely NO, Zisterer DM, Meegan MJ.

Pharmaceuticals (Basel). 2019 Apr 11;12(2). pii: E56. doi: 10.3390/ph12020056.

4.

Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents.

Brindisi M, Ulivieri C, Alfano G, Gemma S, de Asís Balaguer F, Khan T, Grillo A, Chemi G, Menchon G, Prota AE, Olieric N, Lucena-Agell D, Barasoain I, Diaz JF, Nebbioso A, Conte M, Lopresti L, Magnano S, Amet R, Kinsella P, Zisterer DM, Ibrahim O, O'Sullivan J, Morbidelli L, Spaccapelo R, Baldari C, Butini S, Novellino E, Campiani G, Altucci L, Steinmetz MO, Brogi S.

Eur J Med Chem. 2019 Jan 15;162:290-320. doi: 10.1016/j.ejmech.2018.11.004. Epub 2018 Nov 3.

PMID:
30448418
5.

Effect of isouronium/guanidinium substitution on the efficacy of a series of novel anti-cancer agents.

Previtali V, Trujillo C, Amet R, Zisterer DM, Rozas I.

Medchemcomm. 2018 Mar 27;9(4):735-743. doi: 10.1039/c8md00089a. eCollection 2018 Apr 1.

6.

Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cells.

Pollock JK, Greene LM, Nathwani SM, Kinsella P, O'Boyle NM, Meegan MJ, Zisterer DM.

Invest New Drugs. 2018 Aug;36(4):523-535. doi: 10.1007/s10637-017-0543-z. Epub 2018 Feb 19.

PMID:
29460212
7.

Direct effects of phenformin on metabolism/bioenergetics and viability of SH-SY5Y neuroblastoma cells.

Geoghegan F, Chadderton N, Farrar GJ, Zisterer DM, Porter RK.

Oncol Lett. 2017 Nov;14(5):6298-6306. doi: 10.3892/ol.2017.6929. Epub 2017 Sep 14.

8.

Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation.

Kelly PM, Keely NO, Bright SA, Yassin B, Ana G, Fayne D, Zisterer DM, Meegan MJ.

Molecules. 2017 Aug 31;22(9). pii: E1440. doi: 10.3390/molecules22091440.

9.

Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.

O'Boyle NM, Barrett I, Greene LM, Carr M, Fayne D, Twamley B, Knox AJS, Keely NO, Zisterer DM, Meegan MJ.

J Med Chem. 2018 Jan 25;61(2):514-534. doi: 10.1021/acs.jmedchem.6b01917. Epub 2017 May 1.

PMID:
28426931
10.

β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells.

Malebari AM, Greene LM, Nathwani SM, Fayne D, O'Boyle NM, Wang S, Twamley B, Zisterer DM, Meegan MJ.

Eur J Med Chem. 2017 Apr 21;130:261-285. doi: 10.1016/j.ejmech.2017.02.049. Epub 2017 Feb 24.

PMID:
28254699
11.

Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepines.

Greene LM, Butini S, Campiani G, Williams DC, Zisterer DM.

J Cancer. 2016 Dec 4;7(15):2367-2377. eCollection 2016. Review.

13.

Piperlongumine (piplartine) and analogues: Antiproliferative microtubule-destabilising agents.

Meegan MJ, Nathwani S, Twamley B, Zisterer DM, O'Boyle NM.

Eur J Med Chem. 2017 Jan 5;125:453-463. doi: 10.1016/j.ejmech.2016.09.048. Epub 2016 Sep 16.

PMID:
27689728
14.

Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells.

Carr M, Knox AJ, Lloyd DG, Zisterer DM, Meegan MJ.

J Enzyme Inhib Med Chem. 2016;31(sup3):117-130. Epub 2016 Aug 1.

PMID:
27476825
15.

Synthesis, antiproliferative and pro-apoptotic activity of 2-phenylindoles.

Kelly PM, Bright SA, Fayne D, Pollock JK, Zisterer DM, Williams DC, Meegan MJ.

Bioorg Med Chem. 2016 Sep 15;24(18):4075-4099. doi: 10.1016/j.bmc.2016.06.050. Epub 2016 Jun 29.

PMID:
27407030
16.

Involvement of AMP-activated protein kinase in mediating pyrrolo-1,5-benzoxazepine-induced apoptosis in neuroblastoma cells.

Lennon JC, Butini S, Campiani G, O'Meara A, Williams DC, Zisterer DM.

Invest New Drugs. 2016 Oct;34(5):663-76. doi: 10.1007/s10637-016-0366-3. Epub 2016 Jun 22.

PMID:
27334143
17.

The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells.

Nathwani SM, Greene LM, Butini S, Campiani G, Williams DC, Samali A, Szegezdi E, Zisterer DM.

Int J Oncol. 2016 Jul;49(1):74-88. doi: 10.3892/ijo.2016.3518. Epub 2016 May 12.

18.

Development of novel cyclic peptides as pro-apoptotic agents.

Brindisi M, Maramai S, Brogi S, Fanigliulo E, Butini S, Guarino E, Casagni A, Lamponi S, Bonechi C, Nathwani SM, Finetti F, Ragonese F, Arcidiacono P, Campiglia P, Valenti S, Novellino E, Spaccapelo R, Morbidelli L, Zisterer DM, Williams CD, Donati A, Baldari C, Campiani G, Ulivieri C, Gemma S.

Eur J Med Chem. 2016 Jul 19;117:301-20. doi: 10.1016/j.ejmech.2016.04.001. Epub 2016 Apr 5.

PMID:
27150036
19.

Isouronium and N-hydroxyguanidinium derivatives as Cell growth inhibitors: A comparative study.

Kahvedžić-Seljubac A, Nathwani SM, Zisterer DM, Rozas I.

Eur J Med Chem. 2016 Jul 19;117:269-82. doi: 10.1016/j.ejmech.2016.03.047. Epub 2016 Mar 22.

PMID:
27108161
20.

The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15.

Kinsella P, Greene LM, Bright SA, Pollock JK, Butini S, Campiani G, Bauer S, Williams DC, Zisterer DM.

Invest New Drugs. 2016 Apr;34(2):159-67. doi: 10.1007/s10637-016-0331-1. Epub 2016 Feb 17.

PMID:
26885657
21.

Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylazetidin-2-ones as Tubulin-Targeting Antitumor Agents.

Greene TF, Wang S, Greene LM, Nathwani SM, Pollock JK, Malebari AM, McCabe T, Twamley B, O'Boyle NM, Zisterer DM, Meegan MJ.

J Med Chem. 2016 Jan 14;59(1):90-113. doi: 10.1021/acs.jmedchem.5b01086. Epub 2015 Dec 17.

PMID:
26680364
22.

Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells.

Fiore D, Proto MC, Pisanti S, Picardi P, Pagano Zottola AC, Butini S, Gemma S, Casagni A, Laezza C, Vitale M, Ligresti A, Di Marzo V, Zisterer DM, Nathwani S, Williams DC, Campiani G, Gazzerro P, Bifulco M.

Cancer Biol Ther. 2016 Aug 2;17(8):849-58. doi: 10.1080/15384047.2015.1078028.

23.

Combretastatins: more than just vascular targeting agents?

Greene LM, Meegan MJ, Zisterer DM.

J Pharmacol Exp Ther. 2015 Nov;355(2):212-27. doi: 10.1124/jpet.115.226225. Epub 2015 Sep 9. Review.

PMID:
26354991
24.

Unconventional Knoevenagel-type indoles: Synthesis and cell-based studies for the identification of pro-apoptotic agents.

Spallarossa A, Caneva C, Caviglia M, Alfei S, Butini S, Campiani G, Gemma S, Brindisi M, Zisterer DM, Bright SA, Williams CD, Crespan E, Maga G, Sanna G, Delogu I, Collu G, Loddo R.

Eur J Med Chem. 2015 Sep 18;102:648-60. doi: 10.1016/j.ejmech.2015.08.009. Epub 2015 Aug 8.

PMID:
26320088
25.

Induction of apoptosis in oral squamous carcinoma cells by pyrrolo-1,5-benzoxazepines.

O'Callaghan K, Palagano E, Butini S, Campiani G, Williams DC, Zisterer DM, O'Sullivan J.

Mol Med Rep. 2015 Sep;12(3):3748-3754. doi: 10.3892/mmr.2015.3832. Epub 2015 May 25.

PMID:
26005189
26.

Combretastatin (CA)-4 and its novel analogue CA-432 impair T-cell migration through the Rho/ROCK signalling pathway.

Pollock JK, Verma NK, O'Boyle NM, Carr M, Meegan MJ, Zisterer DM.

Biochem Pharmacol. 2014 Dec 15;92(4):544-57. doi: 10.1016/j.bcp.2014.10.002. Epub 2014 Oct 22.

PMID:
25450669
27.

β-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand.

O'Boyle NM, Pollock JK, Carr M, Knox AJ, Nathwani SM, Wang S, Caboni L, Zisterer DM, Meegan MJ.

J Med Chem. 2014 Nov 26;57(22):9370-82. doi: 10.1021/jm500670d. Epub 2014 Nov 17.

PMID:
25369367
28.

Guanidinium-based derivatives: searching for new kinase inhibitors.

Diez-Cecilia E, Kelly B, Perez C, Zisterer DM, Nevin DK, Lloyd DG, Rozas I.

Eur J Med Chem. 2014 Jun 23;81:427-41. doi: 10.1016/j.ejmech.2014.05.025. Epub 2014 May 9.

PMID:
24858546
29.

The novel pyrrolo-1,5-benzoxazepine, PBOX-6, synergistically enhances the apoptotic effects of carboplatin in drug sensitive and multidrug resistant neuroblastoma cells.

Lennon JC, Bright SA, Carroll E, Butini S, Campiani G, O'Meara A, Williams DC, Zisterer DM.

Biochem Pharmacol. 2014 Feb 15;87(4):611-24. doi: 10.1016/j.bcp.2013.12.017. Epub 2014 Jan 6.

PMID:
24406249
30.

PBOX-15 induces apoptosis and improves the efficacy of oxaliplatin in human colorectal cancer cell lines.

Gangemi G, Gazzerro P, Fiore D, Proto MC, Butini S, Gemma S, Casagni A, Laezza C, Vitale M, Ligresti A, Di Marzo V, Zisterer DM, Nathwani S, Clive Williams D, Campiani G, Bifulco M.

Eur J Pharmacol. 2013 Aug 15;714(1-3):379-87. doi: 10.1016/j.ejphar.2013.07.011. Epub 2013 Jul 16. Retraction in: Eur J Pharmacol. 2014 Apr 5;728:190.

PMID:
23872382
31.

Inhibition of late-stage autophagy synergistically enhances pyrrolo-1,5-benzoxazepine-6-induced apoptotic cell death in human colon cancer cells.

Greene LM, Nolan DP, Regan-Komito D, Campiani G, Williams DC, Zisterer DM.

Int J Oncol. 2013 Sep;43(3):927-35. doi: 10.3892/ijo.2013.1989. Epub 2013 Jun 25.

PMID:
23799546
32.

Combretazet-3 a novel synthetic cis-stable combretastatin A-4-azetidinone hybrid with enhanced stability and therapeutic efficacy in colon cancer.

Greene LM, Wang S, O'Boyle NM, Bright SA, Reid JE, Kelly P, Meegan MJ, Zisterer DM.

Oncol Rep. 2013 Jun;29(6):2451-8. doi: 10.3892/or.2013.2379. Epub 2013 Apr 3.

PMID:
23564200
33.

Synthesis and biochemical activities of antiproliferative amino acid and phosphate derivatives of microtubule-disrupting β-lactam combretastatins.

O'Boyle NM, Greene LM, Keely NO, Wang S, Cotter TS, Zisterer DM, Meegan MJ.

Eur J Med Chem. 2013 Apr;62:705-21. doi: 10.1016/j.ejmech.2013.01.016. Epub 2013 Jan 18.

PMID:
23454513
34.

Aromatic bis-N-hydroxyguanidinium derivatives: synthesis, biophysical, and biochemical evaluations.

Kahvedžić A, Nathwani SM, Zisterer DM, Rozas I.

J Med Chem. 2013 Jan 24;56(2):451-9. doi: 10.1021/jm301358s. Epub 2013 Jan 14.

PMID:
23252648
35.

Novel cis-restricted β-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro.

Nathwani SM, Hughes L, Greene LM, Carr M, O'Boyle NM, McDonnell S, Meegan MJ, Zisterer DM.

Oncol Rep. 2013 Feb;29(2):585-94. doi: 10.3892/or.2012.2181. Epub 2012 Dec 10.

PMID:
23232969
36.

The microtubule targeting agent PBOX-15 inhibits integrin-mediated cell adhesion and induces apoptosis in acute lymphoblastic leukaemia cells.

Lysaght J, Verma NK, Maginn EN, Ryan JM, Campiani G, Zisterer DM, Williams DC, Browne PV, Lawler MP, McElligott AM.

Int J Oncol. 2013 Jan;42(1):239-46. doi: 10.3892/ijo.2012.1688. Epub 2012 Nov 6.

PMID:
23135704
37.

The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells.

Greene LM, O'Boyle NM, Nolan DP, Meegan MJ, Zisterer DM.

Biochem Pharmacol. 2012 Sep 1;84(5):612-24. doi: 10.1016/j.bcp.2012.06.005. Epub 2012 Jun 15.

PMID:
22705646
38.

Lead identification of β-lactam and related imine inhibitors of the molecular chaperone heat shock protein 90.

O'Boyle NM, Knox AJ, Price TT, Williams DC, Zisterer DM, Lloyd DG, Meegan MJ.

Bioorg Med Chem. 2011 Oct 15;19(20):6055-68. doi: 10.1016/j.bmc.2011.08.048. Epub 2011 Aug 25.

PMID:
21920765
39.

Synthesis, biochemical and molecular modelling studies of antiproliferative azetidinones causing microtubule disruption and mitotic catastrophe.

O'Boyle NM, Carr M, Greene LM, Keely NO, Knox AJ, McCabe T, Lloyd DG, Zisterer DM, Meegan MJ.

Eur J Med Chem. 2011 Sep;46(9):4595-607. doi: 10.1016/j.ejmech.2011.07.039. Epub 2011 Jul 28.

PMID:
21840628
40.

Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones.

O'Boyle NM, Greene LM, Bergin O, Fichet JB, McCabe T, Lloyd DG, Zisterer DM, Meegan MJ.

Bioorg Med Chem. 2011 Apr 1;19(7):2306-25. doi: 10.1016/j.bmc.2011.02.022. Epub 2011 Feb 17.

PMID:
21397510
41.

BubR1 is required for the mitotic block induced by combretastatin-A4 and a novel cis-restricted ß-lactam analogue in human cancer cells.

Greene LM, Carr M, Keeley NO, Lawler M, Meegan MJ, Zisterer DM.

Int J Mol Med. 2011 May;27(5):715-23. doi: 10.3892/ijmm.2011.633. Epub 2011 Mar 2.

PMID:
21369694
42.

Non-nucleoside inhibitors of human adenosine kinase: synthesis, molecular modeling, and biological studies.

Butini S, Gemma S, Brindisi M, Borrelli G, Lossani A, Ponte AM, Torti A, Maga G, Marinelli L, La Pietra V, Fiorini I, Lamponi S, Campiani G, Zisterer DM, Nathwani SM, Sartini S, La Motta C, Da Settimo F, Novellino E, Focher F.

J Med Chem. 2011 Mar 10;54(5):1401-20. doi: 10.1021/jm101438u. Epub 2011 Feb 14.

PMID:
21319802
43.

PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells.

Maginn EN, Browne PV, Hayden P, Vandenberghe E, MacDonagh B, Evans P, Goodyer M, Tewari P, Campiani G, Butini S, Williams DC, Zisterer DM, Lawler MP, McElligott AM.

Br J Cancer. 2011 Jan 18;104(2):281-9. doi: 10.1038/sj.bjc.6606035. Epub 2010 Dec 21.

44.

Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents.

O'Boyle NM, Carr M, Greene LM, Bergin O, Nathwani SM, McCabe T, Lloyd DG, Zisterer DM, Meegan MJ.

J Med Chem. 2010 Dec 23;53(24):8569-84. doi: 10.1021/jm101115u. Epub 2010 Nov 16.

PMID:
21080725
45.

Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce cell cycle arrest and apoptosis in prostate cancer cells.

Nathwani SM, Cloonan SM, Stronach M, Campiani G, Lawler M, Williams DC, Zisterer DM.

Oncol Rep. 2010 Dec;24(6):1499-507.

PMID:
21042745
46.

Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects.

Carr M, Greene LM, Knox AJ, Lloyd DG, Zisterer DM, Meegan MJ.

Eur J Med Chem. 2010 Dec;45(12):5752-66. doi: 10.1016/j.ejmech.2010.09.033. Epub 2010 Sep 22.

PMID:
20933304
47.

The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance.

Greene LM, Nathwani SM, Bright SA, Fayne D, Croke A, Gagliardi M, McElligott AM, O'Connor L, Carr M, Keely NO, O'Boyle NM, Carroll P, Sarkadi B, Conneally E, Lloyd DG, Lawler M, Meegan MJ, Zisterer DM.

J Pharmacol Exp Ther. 2010 Nov;335(2):302-13. doi: 10.1124/jpet.110.170415. Epub 2010 Aug 10.

PMID:
20699436
48.

Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo.

Bright SA, McElligott AM, O'Connell JW, O'Connor L, Carroll P, Campiani G, Deininger MW, Conneally E, Lawler M, Williams DC, Zisterer DM.

Br J Cancer. 2010 May 11;102(10):1474-82. doi: 10.1038/sj.bjc.6605670. Epub 2010 Apr 20.

49.

Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effects.

Barrett I, Carr M, O'Boyle N, Greene LM, Knox AJ, Lloyd DG, Zisterer DM, Meegan MJ.

J Enzyme Inhib Med Chem. 2010 Apr;25(2):180-94. doi: 10.3109/14756360903169659.

PMID:
20222762
50.

Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment.

Bright SA, Campiani G, Deininger MW, Lawler M, Williams DC, Zisterer DM.

Biochem Pharmacol. 2010 Jul 1;80(1):31-8. doi: 10.1016/j.bcp.2010.02.019. Epub 2010 Mar 3.

PMID:
20206141

Supplemental Content

Loading ...
Support Center